Chimeric
WEBINAR: Chimeric Program Update, November 2023
31:20
Chimeric
Jennifer Chow talks about how Chimeric's CLTX CAR T Therapy Shows a Promising Disease Control Rate
9:24
Chimeric
Chimeric Therapeutics achieves significant progress with latest brain cancer treatment trial
19:01
Chimeric
Webinar: Positive Preliminary Phase 1a Data for CLTX CAR T in Recurrent Brain Cancer Clinical Trial
28:00
Chimeric
Chimeric's Jennifer Chow and Jason Litten feature in ADVANCEMENTS with TED DANSON
6:11
Chimeric
Webinar: Clinical study agreement with MD Anderson for CHM 0201
46:07
Chimeric
Chimeric Therapeutics Ethics Approval for Brain Cancer Study
3:00
Chimeric
Chimeric Therapeutic's IND Approval Path for Innovative CAR T Cell Therapy
26:47
Chimeric
Chimeric Therapeutics at the 2023 NWR Virtual Healthcare Conference
31:06
Chimeric
Chimeric Therapeutics | Bell Potter Healthcare Conference 2022 Presentation
30:16
Chimeric
Chimeric Therapeutics | TechKnow Invest Roadshow 2022
14:13
Chimeric
Chimeric's CEO, Jennifer Chow speaks with Proactive about advancing our NK cell therapy portfolio
3:45
Chimeric
CEO Interviews with Wholesale Investor | Jennifer Chow, Chimeric Therapeutics ASX: CHM
10:06
Chimeric
Jennifer Chow speaks with the FNN to discuss our new agreement with Case Western Reserve University.
3:52
Chimeric
Chimeric Therapeutics' CEO Jennifer Chow talks about expanding the company's cancer trials. ASX: CHM
7:57
Chimeric
Chimeric Therapeutics | Final Results in Phase 1 Trial of CORE NK Platform
21:00
Chimeric
Chimeric Therapeutics Presents at the FNN Investor Event February 2022
13:44
Chimeric
Chimeric CEO Jennifer Chow interviewed on the Finance News Network February 2022
5:04
Chimeric
Chimeric Therapeutics RAAS 2022 Outlook Interview with CEO Jennifer Chow (ASX: CHM)
9:53
Chimeric
Chimeric CEO Jennifer Chow's BIOTECH SHOWCASE 2022 Presentation
19:03
Chimeric
Chimeric obtains the exclusive option agreement to license Natural Killer Cell platform from CWRU
3:29
Chimeric
Chimeric Therapeutics (ASX:CHM): Positive Initial Phase 1 Clinical Data
6:51
Chimeric
Chimeric Transforms Portfolio with a Clinically Validated Off The Shelf Natural Killer Cell Platform
27:34
Chimeric
Chimeric CEO Jennifer Chow speaks to Proactive Investors post positive initial Phase 1 clinical data
6:03
Chimeric
Chimeric Webinar ASX News: CLTX CAR T data shows regional control of tumour recurrence
27:33
Chimeric
Chimeric Therapeutics: CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATA
27:01
Chimeric
Paul Hopper's keynote address at the Emerging Small Caps Summit 2021
19:06
Chimeric
Chimeric Therapeutics' CEO Jennifer Chow presents at the Emerging Small Caps Summit 2021
9:16
Chimeric
Chimeric Therapeutics (ASX: CHM) CEO Jennifer Chow's presentation at the AusBiotech Conference 2021
10:34
Chimeric
Executive Chairman and Founder, Paul Hopper interviewed on The CEO Masterclass by Peter Switzer.
11:29
Chimeric
Chimeric Therapeutics presents at the ASX Small & Mid Cap Conference
17:03
Chimeric
Chimeric Therapeutics: CEO Jennifer Chow talks to Boardroom Media | Market Update
9:44
Chimeric
Jennifer Chow discusses our new CDH17 CAR T cell therapy from the University of Pennsylvania
5:48
Chimeric
Chimeric Therapeutics – ASCO Annual Meeting Presentation Replay
4:55
Chimeric
Sting Operation Using Scorpion Venom to Target Brain Tumors | City of Hope
3:44
Chimeric
COO Jennifer Chow's Corporate Presentation at the NWR Virtual Investor Conference, August 2021.
23:04
Chimeric
Chimeric’s new CDH17 CAR T (ASX:CHM)
8:13